Media coverage about Fortress Biotech (NASDAQ:FBIO) has trended somewhat positive this week, Accern reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fortress Biotech earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 44.8229708126967 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s scoring:
- Fortress Biotech, Inc. (FBIO) stock price is at $5.14 on volume of … – Nasdaq Express (nasdaqexpress.com)
- Caelum Biosciences Announces Clinical Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 16th … – GlobeNewswire (press release) (globenewswire.com)
- Caelum Biosciences Announces Clinical Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 16th International Symposium on Amyloidosis (finance.yahoo.com)
- Checkpoint Therapeutics Initiates Dose Expansion Portion of Phase 1 Trial of Anti-PD-L1 Antibody CK-301 (finance.yahoo.com)
- Mustang Bio to Present at CAR-T Congress USA – NASDAQ.com – Nasdaq (nasdaq.com)
Shares of FBIO stock traded down $0.23 on Friday, hitting $4.92. The stock had a trading volume of 159,568 shares, compared to its average volume of 235,413. The firm has a market cap of $264.41, a P/E ratio of -3.06 and a beta of 0.45. The company has a quick ratio of 2.69, a current ratio of 2.72 and a debt-to-equity ratio of 0.44. Fortress Biotech has a fifty-two week low of $3.13 and a fifty-two week high of $5.54.
TRADEMARK VIOLATION NOTICE: “Fortress Biotech (FBIO) Receives Daily Media Sentiment Rating of 0.10” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3296191/fortress-biotech-fbio-receives-daily-media-sentiment-rating-of-0-10.html.
About Fortress Biotech
Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.